



ASIAN INVESTMENT SERIES 2018

13 March 2018 KPMG Hong Kong 15-16 March 2018 KPMG Shanghai

HONG KONG BIOTECH
INVEST & PARTNERING

AUSTRALIA-CHINA BIOTECH
INVEST & PARTNERING



Nucleus Network

Company Description

Nucleus Network is Australia's leading clinical trials organisation for the conduct of Phase I/early phase clinical trials. We have an 80-bed FDA audited purpose-built clinical trial unit, and more than 150 experienced and motivated staff with strong industry background and expertise. Our excellent reputation is based on our experience of over 500 studies and our specific expertise in First-in-Human oncology and biosimilar studies. Nucleus Network conducts all clinical studies to ICH-GCP guidelines. Approximately 90% of our clients are from overseas including US, European and Asian (including Chinese and Taiwanese) companies who recognize the value of performing studies in Australia with Nucleus to globally recognized standards of High Quality, Speed and Cost Effectiveness.

Pipeline and Developments

We are Australia's largest and most experienced Phase I unit with specialization and expertise in First-in Human, Oncology, Biosimilar and complex Phase I studies.

What we are looking for:

We are keen to partner with organisations who have an interest in performing Phase I/Early Clinical Development in Australia due to the unique attractions of Speed, Quality and Cost. We are also keen to engage with partners who have an understanding of drug development in China.

Contact:

Name: Kevin Wightman

Position: Executive Director, Corporate Development

Company: Nucleus Network

Address: 5th Floor, 89 Commercial Rd, Melbourne, VIC 3004, Australia

Website: <http://www.nucleusnetwork.com.au/>

Phone: +61 434 566 667

Email: k.wightman@nucleusnetwork.com.au

For more information, please visit www.australiabiotechinvest.com.au



Follow us for the latest event update #AusBioInv